Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Piramal Pharma Limited
Pharmaceutical Preparation ManufacturingIndiaNSE: PPLPHARMA.NS
Last verified 6 months agopiramalpharma.com
Piramal Pharma Limited (PPL), a leading player in pharmaceutical preparation manufacturing, is headquartered in India with a significant global operational footprint. Incorporated in 2020 and subsequently listed in October 2022, PPL builds upon the Piramal Group's extensive legacy in healthcare.
This global pharmaceutical company operates across three core business segments: Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics, and India Consumer Healthcare. PPL provides specialised services in drug discovery, development, and manufacturing, including complex active pharmaceutical ingredients (APIs) and sterile injectables.
Its diverse portfolio also encompasses critical care products like anaesthesia and pain management generics, alongside a wide range of over-the-counter healthcare solutions for the Indian market. Piramal Pharma's integrated offerings and strong R&D capabilities position it as a trusted partner in the global pharmaceutical value chain.
85
DitchCarbon score
+43 vs industry average
Piramal Pharma Limited’s score of 85 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Piramal Pharma Limited?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2028
202020212022202320242025202620272028
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Piramal Pharma Limited's reported carbon emissions
Piramal Pharma Limited, an Indian Pharmaceutical Preparation Manufacturing company, reported its latest carbon emissions data for 2025. Its total emissions for 2025 were approximately 618.5 million kg CO2e. This includes Scope 1 emissions of approximately 32.3 million kg CO2e, Scope 2 emissions (market-based) of about 51.4 million kg CO2e, and Scope 3 emissions of around 491.1 million kg CO2e. In 2024, the company's Scope 1 emissions were approximately 43.4 million kg CO2e, market-based Scope 2 emissions were around 79.4 million kg CO2e, and Scope 3 emissions totalled about 499.7 million kg CO2e. For 2023, Piramal Pharma Limited reported Scope 1 emissions of approximately 55.2 million kg CO2e, market-based Scope 2 emissions of about 75.5 million kg CO2e, and Scope 3 emissions of around 450.6 million kg CO2e. In 2022, the company's total emissions were approximately 619.8 million kg CO2e, comprising about 56.6 million kg CO2e from Scope 1, 85.8 million kg CO2e from Scope 2, and 477.4 million kg CO2e from Scope 3.
Piramal Pharma Limited has set ambitious climate commitments, with Science Based Targets initiative (SBTi) validated targets. The company commits to reduce absolute Scope 1 and 2 GHG emissions by 42% by FY2030, using FY2022 as a baseline year. This aligns with the 1.5°C decarbonisation pathway. Additionally, Piramal Pharma Limited aims to reduce absolute Scope 3 GHG emissions from purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, and use of sold products by 25% within the same timeframe. These targets were confirmed by SBTi in September 2024.
Assessing Piramal Pharma Limited as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Piramal Pharma Limited and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Piramal Pharma Limited’s Climate Goals (2030 & 2050)
3 goals2030
42% reduction in Scope 2
Piramal Pharma Limited commits to reduce absolute scope 2 GHG emissions 42% by FY2030 from a FY2022 base year.
At risk42%
2030
42% reduction in Scope 1
Piramal Pharma Limited commits to reduce absolute scope 1 GHG emissions 42% by FY2030 from a FY2022 base year.
At risk42%
2030
25% reduction in scope 3 total
Piramal Pharma Limited also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related acti…
Behind target25%
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
13 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
See details
Active
Carbon Disclosure Project
Sign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Piramal Pharma Limited6 months ago
85
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Frequently asked questions
Common questions about Piramal Pharma Limited’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more